|
Gene: UGT3A2 |
Gene summary for UGT3A2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | UGT3A2 | Gene ID | 167127 |
Gene name | UDP glycosyltransferase family 3 member A2 | |
Gene Alias | UGT3A2 | |
Cytomap | 5p13.2 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q3SY77 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
167127 | UGT3A2 | S014 | Human | Liver | HCC | 2.66e-13 | 4.30e-01 | 0.2254 |
167127 | UGT3A2 | S015 | Human | Liver | HCC | 7.14e-27 | 1.06e+00 | 0.2375 |
167127 | UGT3A2 | S016 | Human | Liver | HCC | 4.24e-18 | 5.04e-01 | 0.2243 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190165422 | Liver | HCC | response to ketone | 119/7958 | 194/18723 | 8.65e-08 | 1.72e-06 | 119 |
GO:19016552 | Liver | HCC | cellular response to ketone | 58/7958 | 96/18723 | 2.99e-04 | 2.13e-03 | 58 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
UGT3A2 | SNV | Missense_Mutation | novel | c.757T>A | p.Phe253Ile | p.F253I | Q3SY77 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-86-6851-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
UGT3A2 | SNV | Missense_Mutation | rs199567567 | c.1406N>T | p.Thr469Met | p.T469M | Q3SY77 | protein_coding | deleterious(0.03) | benign(0.436) | TCGA-86-7711-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | cisplatin | PD |
UGT3A2 | SNV | Missense_Mutation | c.1082N>A | p.Pro361Gln | p.P361Q | Q3SY77 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-86-8073-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
UGT3A2 | SNV | Missense_Mutation | c.1081N>A | p.Pro361Thr | p.P361T | Q3SY77 | protein_coding | deleterious(0.03) | probably_damaging(0.964) | TCGA-86-8073-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
UGT3A2 | SNV | Missense_Mutation | c.31G>C | p.Gly11Arg | p.G11R | Q3SY77 | protein_coding | tolerated(0.36) | benign(0.424) | TCGA-86-A456-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
UGT3A2 | SNV | Missense_Mutation | c.1027N>T | p.Ala343Ser | p.A343S | Q3SY77 | protein_coding | tolerated(0.07) | possibly_damaging(0.71) | TCGA-86-A4JF-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | unknown | PD | |
UGT3A2 | SNV | Missense_Mutation | c.1252G>A | p.Glu418Lys | p.E418K | Q3SY77 | protein_coding | deleterious(0.01) | possibly_damaging(0.676) | TCGA-MN-A4N4-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
UGT3A2 | SNV | Missense_Mutation | c.1411N>A | p.Leu471Ile | p.L471I | Q3SY77 | protein_coding | deleterious(0) | probably_damaging(0.969) | TCGA-18-3411-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
UGT3A2 | SNV | Missense_Mutation | c.1456N>A | p.Leu486Ile | p.L486I | Q3SY77 | protein_coding | deleterious(0.04) | benign(0.072) | TCGA-18-3421-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
UGT3A2 | SNV | Missense_Mutation | novel | c.430N>T | p.Val144Phe | p.V144F | Q3SY77 | protein_coding | tolerated(0.12) | benign(0.109) | TCGA-21-1081-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |